Keyphrases
Omalizumab
100%
Life Studies
100%
Eosinophil Count
28%
Time to Discontinuation
28%
Short-term Treatment
14%
Omalizumab Treatment
14%
Female Gender
14%
Treatment Discontinuation
14%
Treatment Risk
14%
Asthma
14%
Treatment Response
14%
Patient Benefit
14%
Current Guidelines
14%
Guideline Recommendations
14%
Patient's Will
14%
Treatment Initiation
14%
Humanized
14%
Associated Risk Factors
14%
Danish Population
14%
Median Time
14%
Immunology and Microbiology
Allergic Asthma
100%
Omalizumab
100%
Asthma
25%
Eosinophil Count
25%
Monoclonal Anti-IgE
12%
Immunoglobulin E Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
Allergic Asthma
100%
Omalizumab
100%
Asthma
25%
Immunoglobulin E Antibody
12%
Combination Therapy
12%
Monoclonal Anti-IgE
12%